Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells

Biomaterials

Volumn 31, Issue 6, 2010, Pages 1307-1315

  Vigor, Kim L ^a   Kyrtatos, Panagiotis G ^b   Minogue, Shane ^c   Al Jamal, Khuloud T ^d   Kogelberg, Heide ^a   Tolner, Berend ^a   Kostarelos, Kostas ^d   Begent, Richard H ^a   Pankhurst, Quentin A ^e   Lythgoe, Mark F ^b   Chester, Kerry A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e DAVY FARADAY RESEARCH LABORATORY   (United Kingdom)

Author keywords

Antibody; Functionalisation; MRI; Nanoparticles; scFv; Targeting

Indexed keywords

CANCER CELLS; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE PROTEINS; CELLULAR INTERACTION; CONFOCAL LASER SCANNING MICROSCOPY; FUNCTIONALISATION; HYDRODYNAMIC DIAMETER; HYDRODYNAMIC SIZE; IMAGE CONTRASTS; IRON UPTAKE; MRI; SINGLE-CHAIN FV- ANTIBODY FRAGMENTS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; SURFACE COATINGS; TUMOUR CELLS;

CELL MEMBRANES; COATINGS; CONFOCAL MICROSCOPY; FLUID DYNAMICS; HYDRODYNAMICS; IRON OXIDES; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; SUPERPARAMAGNETISM; SURFACE CHEMISTRY; TUMORS;

ANTIBODIES;

CARCINOEMBRYONIC ANTIGEN; DEXTRAN; IRON; MACROGOL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FERRIC ION; FERRIC OXIDE; NANOPARTICLE; RECOMBINANT PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INTERACTION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IRON TRANSPORT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ZETA POTENTIAL; CHEMISTRY; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; IMAGE ENHANCEMENT; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; METHODOLOGY; PATHOLOGY; SYNTHESIS; TUMOR CELL LINE; ULTRASTRUCTURE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; IMMUNOMAGNETIC SEPARATION; NANOPARTICLES; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 72149123166     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.10.036     Document Type: Article

References (47)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8 (2008) 94-107
2. Han Z., Fu A., Wang H., Diaz R., Geng L., Onishko H., et al. Noninvasive assessment of cancer response to therapy. Nat Med 14 (2008) 343-349
3. Lee J.H., Huh Y.M., Jun Y.W., Seo J.W., Jang J.T., Song H.T., et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 13 (2007 Jan) 95-99
4. Renshaw P.F., Owen C.S., McLaughlin A.C., Frey T.G., and Leigh Jr. J.S. Ferromagnetic contrast agents: a new approach. Magn Reson Med 3 (1986) 217-225
5. Wang Y.X., Hussain S.M., and Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11 (2001) 2319-2331
6. Panizzo R.A., Kyrtatos P.G., Price A.N., Gadian D.G., Ferretti P., and Lythgoe M.F. In vivo magnetic resonance imaging of endogenous neuroblasts labelled with a ferumoxide-polycation complex. Neuroimage 44 (2009) 1239-1246
7. Kyrtatos P.G., Lehtolainen P.L., Junemann-Ramirez M., Garcia-Prieto A., Price A.N., Martin J.F., et al. Magnetic tagging increases delivery of circulating progenitors in vascular injury. JACC Cardiovasc Interv 2 (2009) 794-802
8. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of singledomains. Nat Biotechnol 23 (2005) 1126-1136
9. Tolner B., Smith L., Begent R.H., and Chester K.A. Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc 1 (2006) 1006-1021
10. Tolner B., Smith L., Begent R.H., and Chester K.A. Expanded-bed adsorption immobilized-metal affinity chromatography. Nat Protoc 1 (2006) 1213-1222
11. Boehm M.K., Corper A.L., Wan T., Sohi M.K., Sutton B.J., Thornton J.D., et al. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 346 Pt 2 (2000) 519-528
12. Graff C.P., Chester K., Begent R., and Wittrup K.D. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 17 (2004) 293-304
13. Tolner B., Smith L., Hillyer T., Bhatia J., Beckett P., Robson L., et al. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics. EurJ Cancer 43 (2007) 2515-2522
14. Molday R.S., and MacKenzie D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods 52 (1982) 353-367
15. DeNardo S.J., DeNardo G.L., Miers L.A., Natarajan A., Foreman A.R., Gruettner C., et al. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer the rapy. Clin Cancer Res 11 (2005) 7087s-7092s
16. Riemer J., Hoepken H.H., Czerwinska H., Robinson S.R., and Dringen R. Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331 (2004) 370-375
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
18. Patil S., Sandberg A., Heckert E., Self W., and Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 28 (2007) 4600-4607
19. Wilhelm C., Billotey C., Roger J., Pons J.N., Bacri J.C., and Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 24 (2003) 1001-1011
20. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9 (1999) 67-81
21. Hoogenboom H.R. Selecting and screening recombinant antibody libraries. Nat Biotechnol 23 (2005) 1105-1116
22. Berry C.C., Wells S., Charles S., Aitchison G., and Curtis A.S. Cell response to dextran-derivatised iron oxide nanoparticles post intern alisation. Biomaterials 25 (2004) 5405-5413
23. McCarthy J.R., and Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60 (2008) 1241-1251
24. Bulte J.W., and Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellu lar imaging. NMR Biomed 17 (2004) 484-499
25. Artemov D., Mori N., Ravi R., and Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 63 (2003) 2723-2727
26. Gupta A.K., and Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26 (2005) 1565-1573
27. Suwa T., Ozawa S., Ueda M., Ando N., and Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 75 (1998) 626-634
28. Roberts C.J., Williams P.M., Davies J., Dawkes A.C., Sefton J., Edwards J.C., et al. Real-space differentiation of IgG and IgM antibodies deposited on microtitre wells by scanning force microscopy. Langmuir 11 (1995) 1822-1826
29. Funovics M.A., Kapeller B., Hoeller C., Su H.S., Kunstfeld R., Puig S., et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 22 (2004) 843-850
30. Suzuki M., Honda H., Kobayashi T., Wakabayashi T., Yoshida J., and Takahashi M. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic p articles. Noshuyo Byori 13 (1996) 127-132
31. Tiefenauer L.X., Tschirky A., Kuhne G., and Andres R.Y. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson Imaging 14 (1996) 391-402
32. Kato M., Neil T.K., Fearnley D.B., McLellan A.D., Vuckovic S., and Hart D.N. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 12 (2000) 1511-1519
33. Gupta A.K., Naregalkar R.R., Vaidya V.D., and Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed 2 (2007) 23-39
34. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8 (2002) 1172-1181
35. Zhang Y., Kohler N., and Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellul ar uptake. Biomaterials 23 (2002) 1553-1561
36. Berry C.C., Wells S., Charles S., and Curtis A.S. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials 24 (2003) 4551-4557
37. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Ithakissios D.S., and Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanopa rticles. Int J Pharm 221 (2001) 143-152
38. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magicbullet. Clin Cancer Res 7 (2001) 223-225
39. Bailon P., and Won C.Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6 (2009) 1-16
40. Mailander V., Lorenz M.R., Holzapfel V., Musyanovych A., Fuchs K., Wiesneth M., et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol 10 (2008) 138-146
41. Weissleder R., Elizondo G., Wittenberg J., Rabito C.A., Bengele H.H., and Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
42. Sun C., Sze R., and Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI.J. Biomed Mater Res A 78 (2006) 550-557
43. Matuszewski L., Persigehl T., Wall A., Schwindt W., Tombach B., Fobker M., et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labelling efficiency. Radiology 235 (2005) 155-161
44. Wilhelm C., and Gazeau F. Universal cell labelling with anionic magnetic nanoparticles. Biomaterials 29 (2008) 3161-3174
45. Cartiera M.S., Johnson K.M., Rajendran V., Caplan M.J., and Saltzman W.M. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30 (2009) 2790-2798
46. Thorek D.L., Chen A.K., Czupryna J., and Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34 (2006) 23-38
47. Briley-Saebo K., Bjornerud A., Grant D., Ahlstrom H., Berg T., and Kindberg G.M. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 316 (2004) 315-323